abs373.txt	introduction		bavituximab	is	an	immunomodulatory	chimeric	monoclonal	antibodythat	inhibits	phosphatidylserine	signaling		which	promotes	innate	and	adaptiveimmune	responses		in	this	phase	ib	trial	we	evaluated	the	safety		tolerability	and	preliminary	antitumor	activity	of	pemetrexed		carboplatin		bavituximab	inadvanced	non-small-cell	lung	cancer	(nsclc)	patients	and	methods		patients	with	advanced	nonsquamous	nsclc	and	performancestatus	0	or	1	were	treated	with	pemetrexed	500	mg/m2	and	carboplatin	area	underthe	curve	6	once	every	3	weeks	for	up	to	6	cycles		with	concurrent	bavituximab(0	3		1		or	3	mg/kg)	intravenously	weekly		using	a	standard	3+3	design		at	themaximum	identified	dose		additional	patients	were	enrolled	to	furthercharacterize	the	safety	profile		the	primary	objective	was	to	characterize	thesafety		determine	the	dose-limiting	toxicities	(dlts)		and	establish	therecommended	phase	ii	dose	of	bavituximab	in	combination	with	pemetrexed	andcarboplatin	in	incurable	stage	iv	nonsquamous	nsclc	results		between	march	29		2011	and	december	30		2013		26	patients	were	enrolled	three	patients	each	were	enrolled	into	dose	escalation	cohorts	of	bavituximab(0	3		1		and	3	mg/kg)		therapy	was	well	tolerated	with	no	dlts		and	toxicitieswere	consistent	with	those	expected	from	pemetrexed/carboplatin		overall	responsewas	28%		with	a	median	progression-free	and	overall	survival	of	4	8	months	and12	2	months		respectively	conclusion		the	combination	of	pemetrexed		carboplatin		bavituximab	is	welltolerated		however		with	toxicities	and	preliminary	efficacy	signal	similar	topemetrexed/carboplatin	alone		further	studies	of	bavituximab	should	focus	on	waysto	enhance	its	immunomodulatory	role	
